Axial Spondyloarthritis Clinical Trial
Official title:
Physical Activity in Axial Spondyloarthritis: Development and Implementation of an Evidence-Based Health Technology Approach to Improve Adherence to Recommended Guidelines
Despite the known benefits of physical activity, the majority of Canadians fail to meet recommended guidelines. Patients with axial spondyloarthritis (axSpA) also fail to meet recommended guidelines. Exercise, a critical component of physical activity, is considered the cornerstone of axSpA management. Simple health technologies such as mobile phone messaging and email can be useful tools to increase engagement in regular physical activity among the general public and patients with chronic disease. As such, the aim of this research project is to develop and test a patient-centered strategy that provides education on the importance of physical activity and utilizes existing health technologies (such as smart phone applications) to encourage regular participation in physical activity. The results of this study are expected to demonstrate that patients with axSpA will increase their daily engagement in physical activity, and therefore improve symptoms, function and overall quality of life.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05031767 -
Remote Monitoring of Axial Spondyloarthritis
|
N/A | |
| Completed |
NCT05162937 -
to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis
|
Phase 2 | |
| Completed |
NCT03622658 -
Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis
|
Phase 2 | |
| Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
| Terminated |
NCT02437162 -
A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis
|
Phase 3 | |
| Enrolling by invitation |
NCT06072859 -
The Impact of Simulated Forest Immersion Therapy on Pain and Anxiety in Patients Axial Spondyloarthritis (axSpA)
|
N/A | |
| Completed |
NCT02552212 -
Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
|
Phase 3 | |
| Active, not recruiting |
NCT02687620 -
Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
|
||
| Active, not recruiting |
NCT01944163 -
The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain
|
N/A | |
| Completed |
NCT00844805 -
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
|
Phase 3 | |
| Terminated |
NCT02897115 -
A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment
|
Phase 4 | |
| Completed |
NCT05019547 -
The Turkish Version of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity
|
||
| Recruiting |
NCT03738956 -
Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial
|
Phase 2/Phase 3 | |
| Completed |
NCT04679649 -
Physiotherapy of Axial Spondyloarthritis
|
N/A | |
| Enrolling by invitation |
NCT02962479 -
Is the Human Microbiome Altered in Patients With Axial Spondyloarthritis?
|
N/A | |
| Completed |
NCT04485078 -
Investigation of Central Sensitization Frequency and Related Factors in Axial Spondyloarthritis Patients
|
||
| Recruiting |
NCT05812157 -
Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17
|
N/A | |
| Completed |
NCT03039088 -
PREDICT-SpA - French Epidemiological Study of the Evaluation of the Impact of Fibromyalgia in the TNF Alpha Treatment Effect in Axial Spondyloarthritis in Both Anti-TNF naïve and - Experienced Patients
|
||
| Completed |
NCT04368494 -
Exercise Therapy in Patients With Axial Spondyloarthritis
|
N/A | |
| Completed |
NCT03270501 -
Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation
|
Phase 3 |